KZIA חוב לטווח קצר של החברה Kazia Therapeutics Ltd

Kazia Therapeutics (KZIA) develops treatments for severe brain tumors, minimizing costs and risks through global collaborative trials. This trading chart confirms the asset's dynamics, where the indicator stands at 0.00. Cloud AI services optimize data analysis, reducing headcount. High authority within the scientific community ensures the brand maintains a stable status as a promising developer in the field of oncology.

This metric assesses the issuer's solvency by aggregating all liabilities with a maturity of up to twelve months to analyze default risks. The trend of short-term debt is critical for Kazia Therapeutics (KZIA), as outsourcing production and trials minimizes capital expenditures, shifting the primary financial focus toward managing current liquidity and operational debts.